Yeah, first, let me comment on the unmet need and bronchiectasis. Um, the unmet need is huge. We've had, um, really no approved therapies until recently. We have a Uh, a therapy now approved for use that's really an anti-inflammatory. And if you think about the pathophysiology of bronchiectasis, which I'm sure some of my colleagues have already talked about, uh, in the vicious cycle or circle or vortex, we like to call it, it's this complicated diagram that you see in all these, uh, papers we publish that, uh, speak to the fact that this is a chronic inflammatory disease. And what drives the inflammation, In some cases, is the inability to clear, um, secretions. In other cases, it's colonizations with certain organisms, uh, pathogens, and it's the inflammation, uh, of the immune system fighting those pathogens or trying to clear them. Um, and in this context, it's, it's kind of a circular cascade, um, and you see the inflammation sometimes can be, Overabundant or the neutrophils driving that inflammation can be over, overreactive or overactive, and we see damage to the underlying airway because of that inflammation. So, presumably, if we, um, you know, presumably we have several areas that we can target. I mean, if we could diminish the inflammation, i.e., an anti-inflammatory approach, that could be beneficial. There'd be less tissue destruction. Less, um, airway obstruction, less breathing compromise, etc. um, less symptoms, less cough, less sputum. If we could remove the colonizing organisms or infecting organisms, then presumably we'd have a lot less inflammation. So targeting the organisms has been a strategy for a long time. It hasn't necessarily worked that well. We do have some tools in that toolkit. We just don't have any approved therapies and I'm happy to comment on that later. Um, another strategy is simply removing the debris and the secretions and the things that the patient breathes in every day into their airway. Uh, and that's a pulmonary toilet or hygiene, you know, we used to call it that. It's really clearance and hygiene or pulmonary hygiene, and it's, uh, washing out the airway, uh, trying to get the patient to produce secretions and relieve their airways and mucus plugs. So really what I tell patients is to prevent them from building up. Um, or occurring in the first place. So, there's, it's really this multimodal approach where we are, um, Undertaking, you know, an anti-inflammatory, and antimicrobial, uh, an anti-structural, you know, debris type approach, uh, that we target this disease. And there are other targets out there too. I mean, there's probably other things driving inflammation that we could target, um, in the, along the lines of the anti-inflammatory, uh, spectrum. So, it's a complicated disease, but I, I do think we are making some strides in, in certain areas.
Presenter
